Targets › ACP3
1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2031.
A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma..; FUNCTION: [Isoform 2]: Tyrosine phosphatase that acts as a tumor suppressor of prostate cancer through dephosphorylation…. (UniProt, P15309)
Open in Phaseline: the race on ACP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dendreon | Sipuleucel-T Prostatic acid phosphatase binding agent | ACP3 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate Adenocarcinoma | Dec 2031 |
Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2) Prostate Cancer (1) Metastatic Castration-resistant Prostate Cancer (1) Metastatic Castration-Resistant Prostate Adenocarcinoma (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.